Official Title

Investigations on Improving Docosahexaenoic and Arachidonic Acid Content in Preterm Infant Formula
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    fish oil ...
  • Study Participants

    66
The investigators examined the effect of different levels of docosahexaenoic aicd (a long chain polyunsaturated fatty acid) intake on the fatty acid composition of plasma and erythrocyte phospholipids and on the maturity of visually evoked potentials in preterm infants. As a secondary outcome the conversion of linoleic acid and alpha linolenic acid into their corresponding long chain polyunsaturated fatty acids was studied.

Preterm infants were randomized in a double-blind fashion to one of three formulas containing different amounts of docosahexaenoic acid during the first two weeks of postnatal life. A control group received human milk. Blood samples were collected at study entry and 14 and 28 days thereafter. Uniformly 13C-labeled linoleic acid and alpha linolenic acid were applied orally before blood sampling at day 28. At postconceptional ages 48 weeks and 56 weeks visually evoked potentials were recorded.
Study Started
Jun 30
1995
Primary Completion
Mar 31
1998
Study Completion
Mar 31
1998
Last Update
Feb 21
2011
Estimate

Dietary Supplement low docosahexaenoic acid formula

Dietary Supplement medium docosahexaenoic acid formula

Dietary Supplement high docosahexaenoic acid formula

Dietary Supplement breast milk

a non randomized group of breast milk fed infants was included

low docosahexaenoic acid formula Experimental

medium docosahexaenoic acid formula Experimental

high docosahexaenoic acid formula Experimental

human milk Active Comparator

Criteria

Inclusion Criteria:

preterm birth
birth weight between 1000 and 2200 g
more than 80 % of energy intake from infant formula or human milk at enrollment

Exclusion Criteria:

apparent genetic, gastrointestinal or metabolic disorders
artificial ventilation or oxygen supply > 30% at the time of enrollment
administration of parenteral fat emulsion (> 1 g/kg/day for more than seven days) before or after study entry
No Results Posted